机译:Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies
Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences;
Biostatistics,AstraZeneca;
Medical Safety Science,AstraZenecaQuantitative Clinical Pharmacology Data Services, R&D,AstraZenecaQuantitative Clinical Pharmacology,AstraZenecaClinical Development,AstraZeneca;
acalabrutinib; ACP‐5862; B‐cell; BTK inhibitor; Calquence; chronic; exposure–efficacy; exposure–response; exposure–safety; leukaemia; lymphocytic; obinutuzumab; pharmacokinetics;